Petr Widimsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Petr Widimsky has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Petr Toušek
Department of Cardiology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Prague, Czech Republic
8 shared publications - Viktor Kocka
Department of Cardiology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Šrobárova 50, Prague 100 34, Czech Republic
8 shared publications - Zuzana Motovska
Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
5 shared publications Libor Lisa
From the Third Faculty of Medicine, Charles University, Prague, Czech Republic (P.W., R.P., P.T., H.L., T.B., L.L., V.K.); Department of Cardiology, University Hospital Kralovske Vinohrady, Prague (P.W., R.P., P.T., H.L., T.B., L.L., V.K.); and Department of Cardiology, Central Military Hospital, Prague, Czech Republic (M.M., J.V., M.H.).
3 shared publications- Martin Malý
Department of Medicine First Faculty of Medicine Charles University Military University Hospital Prague Czech Republic
3 shared publications Robert Petr
3 shared publications
Latest Publications
- Open Access
- 29 September 2025
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
¿Cuán importante es la telemedicina en la fase inicial del IMCEST?
- 29 September 2025
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Open Access¿Cuán importante es la telemedicina en la fase inicial del IMCEST?
- Open Access
- 1 April 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (4) , 963-971
Neutrophil Extracellular Traps and Thrombolysis Resistance: New Insights for Targeting Therapies
BACKGROUND: Thrombosis is linked to neutrophil release of neutrophil extracellular traps (NETs). NETs are proposed as a mechanism of resistance to thrombolysis. This study intends to analyze the composition of thrombi retrieved after mechanical thrombectomy, estimate the age and organization of thrombi, and evaluate associations with the use of thrombolysis, antiplatelets, and heparin. METHODS: This retrospective observational study involved 72 samples (44 from cerebral and 28 coronary arteries), which were stained with hematoxylin and eosin, anti-NE (neutrophil elastase) antibody, and anti-histone H2B (histone H2B) antibody, representing different components in NET formation, all detectable during the later stages of NETosis, for histochemical and digital quantification of NET content. The histological and morphological evaluations of the specimens were correlated, through univariate and mediation analyses, with clinical information and therapy administered before intervention. RESULTS: The results demonstrated that the composition of cerebral and coronary thrombi differs, and there were significantly more lytic cerebral thrombi than coronary thrombi (66% versus 14%; P =0.005). There was a considerably higher expression of NETs in the cerebral thrombi as testified by the higher expression of H2B ( P =0.031). Thrombolysis was remarkably associated with higher NE positivity (average marginal effect, 6.461 [95% CI, 0.7901–12.13]; P =0.02555), regardless of the origin of thrombi. There was no notable association between the administration of antiaggregant therapy/heparin and H2B/NE amount when adjusted for the thrombus location. Importantly, the age of the thrombus was the only independent predictor of NET content without any mediation of the thrombolytic treatment ( P =0.014). CONCLUSIONS: The age of the thrombus is the driving force for NET content, which correlates with impaired clinical outcomes. The therapy that is currently administered does not modify NET content. This study supports the need to investigate new pharmacological approaches added to thrombolysis to prevent NET formation or enhance their disruption, such as recombinant human DNase I (deoxyribonuclease I).
- 1 April 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (4) , 963-971
Open AccessNeutrophil Extracellular Traps and Thrombolysis Resistance: New Insights for Targeting Therapies
BACKGROUND: Thrombosis is linked to neutrophil release of neutrophil extracellular traps (NETs). NETs are proposed as a mechanism of resistance to thrombolysis. This study intends to analyze the composition of thrombi retrieved after mechanical thrombectomy, estimate the age and organization of thrombi, and evaluate associations with the use of thrombolysis, antiplatelets, and heparin. METHODS: This retrospective observational study involved 72 samples (44 from cerebral and 28 coronary arteries), which were stained with hematoxylin and eosin, anti-NE (neutrophil elastase) antibody, and anti-histone H2B (histone H2B) antibody, representing different components in NET formation, all detectable during the later stages of NETosis, for histochemical and digital quantification of NET content. The histological and morphological evaluations of the specimens were correlated, through univariate and mediation analyses, with clinical information and therapy administered before intervention. RESULTS: The results demonstrated that the composition of cerebral and coronary thrombi differs, and there were significantly more lytic cerebral thrombi than coronary thrombi (66% versus 14%; P =0.005). There was a considerably higher expression of NETs in the cerebral thrombi as testified by the higher expression of H2B ( P =0.031). Thrombolysis was remarkably associated with higher NE positivity (average marginal effect, 6.461 [95% CI, 0.7901–12.13]; P =0.02555), regardless of the origin of thrombi. There was no notable association between the administration of antiaggregant therapy/heparin and H2B/NE amount when adjusted for the thrombus location. Importantly, the age of the thrombus was the only independent predictor of NET content without any mediation of the thrombolytic treatment ( P =0.014). CONCLUSIONS: The age of the thrombus is the driving force for NET content, which correlates with impaired clinical outcomes. The therapy that is currently administered does not modify NET content. This study supports the need to investigate new pharmacological approaches added to thrombolysis to prevent NET formation or enhance their disruption, such as recombinant human DNase I (deoxyribonuclease I).
- Open Access
- 4 June 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (6) , 508
MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty
Aim. This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI). Methods and Results. The analysis included 598 patients randomized in the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI). The measurements of miRNAs were performed by using a novel miRNA immunoassay method. The association of miRNAs with the occurrence of the ischemic endpoint (EP) (cardiovascular death, nonfatal MI, or stroke) and bleeding were analyzed. The miR-223-3p level was significantly related to an increased risk of occurrence of the ischemic EP within 30 days (odds ratio (OR) = 15.74, 95% confidence interval (CI): 2.07–119.93, p = 0.008) and one year (OR = 3.18, 95% CI: 1.40–7.19, p = 0.006), respectively. The miR-126-3p to miR-223-3p ratio was related to a decreased risk of occurrence of EP within 30 days (OR = 0.14, 95% CI: 0.03–0.61, p = 0.009) and one year (OR = 0.37, 95% CI: 0.17–0.82, p = 0.014), respectively. MiRNAs were identified as independent predictors of EP even after adjustment for confounding clinical predictors. Adding miR-223-3p and miR-126-3p to miR-223-3p ratios as predictors into the model calculating the ischemic risk significantly increased the predictive accuracy for combined ischemic EP within one year more than using only clinical ischemic risk parameters. No associations between miRNAs and bleeding complications were identified. Conclusion. The miR-223-3p and the miR-126-3p are promising independent predictors of thrombotic events and can be used for ischemic risk stratification after AMI.
- 4 June 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (6) , 508
Open AccessMiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty
Aim. This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI). Methods and Results. The analysis included 598 patients randomized in the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI). The measurements of miRNAs were performed by using a novel miRNA immunoassay method. The association of miRNAs with the occurrence of the ischemic endpoint (EP) (cardiovascular death, nonfatal MI, or stroke) and bleeding were analyzed. The miR-223-3p level was significantly related to an increased risk of occurrence of the ischemic EP within 30 days (odds ratio (OR) = 15.74, 95% confidence interval (CI): 2.07–119.93, p = 0.008) and one year (OR = 3.18, 95% CI: 1.40–7.19, p = 0.006), respectively. The miR-126-3p to miR-223-3p ratio was related to a decreased risk of occurrence of EP within 30 days (OR = 0.14, 95% CI: 0.03–0.61, p = 0.009) and one year (OR = 0.37, 95% CI: 0.17–0.82, p = 0.014), respectively. MiRNAs were identified as independent predictors of EP even after adjustment for confounding clinical predictors. Adding miR-223-3p and miR-126-3p to miR-223-3p ratios as predictors into the model calculating the ischemic risk significantly increased the predictive accuracy for combined ischemic EP within one year more than using only clinical ischemic risk parameters. No associations between miRNAs and bleeding complications were identified. Conclusion. The miR-223-3p and the miR-126-3p are promising independent predictors of thrombotic events and can be used for ischemic risk stratification after AMI.
- 25 March 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (14) , 1285-1286
Jiri Widimsky MD
- 25 March 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (14) , 1285-1286
Jiri Widimsky MD
- Open Access
- 24 December 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (1) , 24
Modified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic
The COVID-19 pandemic presents several challenges for managing patients with acute coronary syndrome (ACS). Modified treatment algorithms have been proposed for the pandemic. We assessed new algorithms proposed by The European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Acute Cardiovascular Care Association (ACCA) on patients with ACS admitted to the hospital during the COVID-19 pandemic. The COVID-19 period group (CPG) consisted of patients admitted into a high-volume centre in Prague between 1 February 2020 and 30 May 2020 (n = 181). The reference group (RG) included patients who had been admitted between 1 October 2018 and 31 January 2020 (n = 834). The proportions of patients with different types of ACS admitted before and during the pandemic did not differ significantly: in all ACS patients, KILLIP III-IV class was present in 13.9% in RG and in 9.4% of patients in CPG (p = 0.082). In NSTE-ACS patients, the ejection fraction was lower in the CPG than in the RG (44.7% vs. 50.7%, respectively; p < 0.001). The time from symptom onset to first medical contact did not differ between CPG and RG patients in the respective NSTE-ACS and STEMI groups. The time to early invasive treatment in NSTE-ACS patients and the time to reperfusion in STEMI patients were not significantly different between the RG and the CPG. In-hospital mortality did not differ between the groups in NSTE-ACS patients (odds ratio in the CPG 0.853, 95% confidence interval (CI) 0.247 to 2.951; p = 0.960) nor in STEMI patients (odds ratio in CPG 1.248, 95% CI 0.566 to 2.749; p = 0.735). Modified treatment strategies for ACS during the COVID-19 pandemic did not cause treatment delays. Hospital mortality did not differ.
- 24 December 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (1) , 24
Open AccessModified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic
The COVID-19 pandemic presents several challenges for managing patients with acute coronary syndrome (ACS). Modified treatment algorithms have been proposed for the pandemic. We assessed new algorithms proposed by The European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Acute Cardiovascular Care Association (ACCA) on patients with ACS admitted to the hospital during the COVID-19 pandemic. The COVID-19 period group (CPG) consisted of patients admitted into a high-volume centre in Prague between 1 February 2020 and 30 May 2020 (n = 181). The reference group (RG) included patients who had been admitted between 1 October 2018 and 31 January 2020 (n = 834). The proportions of patients with different types of ACS admitted before and during the pandemic did not differ significantly: in all ACS patients, KILLIP III-IV class was present in 13.9% in RG and in 9.4% of patients in CPG (p = 0.082). In NSTE-ACS patients, the ejection fraction was lower in the CPG than in the RG (44.7% vs. 50.7%, respectively; p < 0.001). The time from symptom onset to first medical contact did not differ between CPG and RG patients in the respective NSTE-ACS and STEMI groups. The time to early invasive treatment in NSTE-ACS patients and the time to reperfusion in STEMI patients were not significantly different between the RG and the CPG. In-hospital mortality did not differ between the groups in NSTE-ACS patients (odds ratio in the CPG 0.853, 95% confidence interval (CI) 0.247 to 2.951; p = 0.960) nor in STEMI patients (odds ratio in CPG 1.248, 95% CI 0.566 to 2.749; p = 0.735). Modified treatment strategies for ACS during the COVID-19 pandemic did not cause treatment delays. Hospital mortality did not differ.
- Open Access
- 1 April 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (13) , 1323-1325
Otto Klein from Prague University Hospital performed the world first diagnostic cardiac catheterization in 11 Czech patients in 1929
When the Nobel Prize in Physiology and Medicine was awarded to Andre Cournand and Werner Forssmann in 1956 for developing cardiac catheterization, the Nobel Committee was not aware about the pioneering work of Dr Otto Klein. However, W. Forssmann mentioned him in his Nobel Lecture on 11 December 1956: ‘Nevertheless, in 1930, about 6 months after my first publication, Otto Klein reported from Nonnrenbruch’s Prague clinic on a series of patients whose heart minute-volumes he had ascertained according to Fick’s principle, by means of the heart catheter. This procedure has its place even today in the standard practice of heart and lung clinics’ (https://www.nobelprize.org/prizes/medicine/1956/forssmann/lecture/).
- 1 April 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (13) , 1323-1325
Open AccessOtto Klein from Prague University Hospital performed the world first diagnostic cardiac catheterization in 11 Czech patients in 1929
When the Nobel Prize in Physiology and Medicine was awarded to Andre Cournand and Werner Forssmann in 1956 for developing cardiac catheterization, the Nobel Committee was not aware about the pioneering work of Dr Otto Klein. However, W. Forssmann mentioned him in his Nobel Lecture on 11 December 1956: ‘Nevertheless, in 1930, about 6 months after my first publication, Otto Klein reported from Nonnrenbruch’s Prague clinic on a series of patients whose heart minute-volumes he had ascertained according to Fick’s principle, by means of the heart catheter. This procedure has its place even today in the standard practice of heart and lung clinics’ (https://www.nobelprize.org/prizes/medicine/1956/forssmann/lecture/).
- Open Access
- 1 September 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (33) , 3018
Thrombectomy for stroke by cardiologists
Cardiologists are willing to cooperate with neurologists / strokologists to help patients with acute ischemic stroke
- 1 September 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (33) , 3018
Open AccessThrombectomy for stroke by cardiologists
Cardiologists are willing to cooperate with neurologists / strokologists to help patients with acute ischemic stroke
- Open Access
- 28 August 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (17) , 1567-1573
The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke
Stroke is a vascular disease with cerebral consequences, where the heart is a key player. It is defined as ‘a clinical syndrome typified by rapidly developing signs of focal or global disturbance of cerebral functions, lasting more than 24 h or leading to death, with no apparent causes other than of vascular origin’. 1 The incidence of stroke varies between 100–400 per 100 000 per year 2 and mortality ranks second after coronary heart disease. 3 Beyond mortality stroke is the largest single cause of physical disability in adults, second cause of dementia (after Alzheimer disease), major cause of depression, falls and epilepsy in the elderly. Stroke hence presents a tremendous burden both on patients as well as families and health care systems. Despite decreasing mortality rates in recent years, 4 hospitalization numbers are increasing 3 and long-term care and secondary prevention of stroke will have to move even more in the focus of clinical and health economic efforts. Most strokes (85%) are ischaemic and 15–20% are haemorrhagic. At least 25% of ischaemic strokes are of definite cardio-embolic origin and about a further 20–25% are of suspected cardiac origin or involvement. Most importantly, stroke is clearly recognized as a preventable disease.
- 28 August 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (17) , 1567-1573
Open AccessThe role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke
Stroke is a vascular disease with cerebral consequences, where the heart is a key player. It is defined as ‘a clinical syndrome typified by rapidly developing signs of focal or global disturbance of cerebral functions, lasting more than 24 h or leading to death, with no apparent causes other than of vascular origin’. 1 The incidence of stroke varies between 100–400 per 100 000 per year 2 and mortality ranks second after coronary heart disease. 3 Beyond mortality stroke is the largest single cause of physical disability in adults, second cause of dementia (after Alzheimer disease), major cause of depression, falls and epilepsy in the elderly. Stroke hence presents a tremendous burden both on patients as well as families and health care systems. Despite decreasing mortality rates in recent years, 4 hospitalization numbers are increasing 3 and long-term care and secondary prevention of stroke will have to move even more in the focus of clinical and health economic efforts. Most strokes (85%) are ischaemic and 15–20% are haemorrhagic. At least 25% of ischaemic strokes are of definite cardio-embolic origin and about a further 20–25% are of suspected cardiac origin or involvement. Most importantly, stroke is clearly recognized as a preventable disease.
- Open Access
- 14 August 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (31) , 2389-2390
Stroke management by cardiologists
Catheter-based acute ischaemic stroke management by cardiologists; promises and premises
- 14 August 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (31) , 2389-2390
Open AccessStroke management by cardiologists
Catheter-based acute ischaemic stroke management by cardiologists; promises and premises
- 21 July 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (47) , 3535-3537
Mechanical circulatory support: harm without benefit? Fascinated by devices, cardiologists may lose common sense.
- 21 July 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (47) , 3535-3537
Mechanical circulatory support: harm without benefit? Fascinated by devices, cardiologists may lose common sense.